Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

B HONG KONG, April 28, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that ivonescimab, the company’s first-in-class PD-1/VEGF bispecific antibody,…
posteditor
posteditor
Articles: 17424

Other News